ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Baqsimi (nasal glucagon) — U.S. revenue [legacy] by Quarter
Baqsimi (nasal glucagon) — U.S. revenue ($M) [legacy] ($M)
Eli Lilly Baqsimi (nasal glucagon) — U.S. revenue [legacy]: $1.10M in Q4 2024, down 91.3% from a year earlier. That is the lowest of the 9 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2024 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2025-02-19) ↗
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Baqsimi (nasal glucagon) — U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2024 | Dec 31, 2024 | 1.10 | -91.3% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2024 | Sep 30, 2024 | 8.20 | +115.8% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 3.30 | -99.5% | Form 10-Q (filed 2024-08-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 12.6 | -59.2% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2023 | Sep 30, 2023 | 3.80 | -89.2% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 606 | +2,680.7% | Form 10-Q (filed 2024-08-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 30.9 | – | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 35.2 | – | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 21.8 | – | Form 10-Q (filed 2023-08-08) ↗ |
Cite this data
StockData. (2026). Eli Lilly Baqsimi (nasal glucagon) — U.S. revenue [legacy] ($M), quarterly Q2 2022–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-baqsimi-us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.